Pathophysiology and Standard of Care in Generalized Myasthenia Gravis

Author(s):

Nicholas J. Silvestri, MD, FAAN,Ali Habib, MD

Key Takeaways

MG involves antibodies targeting acetylcholine receptors, disrupting neuromuscular transmission and causing muscle weakness.
New therapeutic targets include MuSK and LRP4, offering potential for novel treatment strategies.
Standard gMG treatment includes acetylcholinesterase inhibitors, corticosteroids, and immunosuppressants.
Emerging therapies focus on monoclonal antibodies and complement inhibitors for targeted disease management.

Panelists discuss how the current understanding of myasthenia gravis pathophysiology is informing the development of targeted treatments, alongside reviewing the standard of care for generalized myasthenia gravis (gMG).

EP: 1.Generalized Myasthenia Gravis Presentation and Diagnosis

EP: 2.Generalized Myasthenia Gravis Classification and Treatment Strategy

Now Viewing

EP: 3.Pathophysiology and Standard of Care in Generalized Myasthenia Gravis

EP: 4.Outcome Measures in Generalized Myasthenia Gravis

EP: 5.Complement Inhibitors for Treatment of Generalized Myasthenia Gravis

EP: 6.Neonatal Fc Receptors in Treatment of Generalized Myasthenia Gravis

EP: 7.Factors Guiding Treatment Selection in Generalized Myasthenia Gravis

EP: 8.Combination Therapy in Generalized Myasthenia Gravis and Treatment of Newly Diagnosed Patients

EP: 9.Nipocalimab and FcRn Inhibitors in Generalized Myasthenia Gravis

EP: 10.Dosing Regimens and Treatment Efficacy of FcRn Inhibitors in Generalized Myasthenia Gravis

EP: 11.Use of Targeted Agents in Generalized Myasthenia Gravis

EP: 12.Management of Generalized Myasthenia Gravis in Pediatric Patients

EP: 13.Unmet Needs in Generalized Myasthenia Gravis

EP: 14.Generalized Myasthenia Gravis Pipeline

EP: 15.New Data from AANEM 2024 in Generalized Myasthenia Gravis

EP: 16.Clinical Pearls for Management of Generalized Myasthenia Gravis

Video content above is prompted by the following:

What is our current understanding of the underlying pathophysiology of MG? How is this being utilized to design targeted agents to treat gMG?
What is the standard of care for gMG?

Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.

Subscribe Now!